Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.39 |
| ▸ | DAGLB | Q8NCG7 | 4/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797310 | 0.91 | CAMKK1 (0.39) | EGFRLTA4HKMT2AERBB2 | |
| SCHEMBL4620158 | 0.89 | CAMKK1 (0.38) | EGFRLTA4HERBB2 | |
| SCHEMBL3523231 | 0.83 | SPHK2 (0.44) | EGFRERBB2 | |
| SCHEMBL2799815 | 0.82 | DAGLB (0.39) | DAGLBLTA4HPTGS2F2RL3 | |
| SCHEMBL3521645 | 0.79 | EGFR (0.65) | EGFRERBB2 | |
| SCHEMBL3428136 | 0.79 | F2RL3 (0.38) | DAGLBF2RL3 | |
| SCHEMBL4923369 | 0.77 | S1PR1 (0.34) | KMT2ASRCERBB2KDR | |
| SCHEMBL3429416 | 0.76 | F2RL3 (0.36) | DAGLBKMT2AF2RL3 | |
| SCHEMBL3283198 | 0.74 | SLC2A1 (0.44) | EGFRKMT2AKDR | |
| SCHEMBL2797321 | 0.74 | CPT1A (0.36) | LTA4HKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168143-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB | 2010-07-01 | — | — | US | disclosed |
| EP-1979344-A2 | N-(2,3-DIFLUOROPHENYL)-2-[4-({7-METHOXY-5-[(2R)-PIPERIDIN.-2-YLMETHOXY]QUINAZOLIN-4-YL}AMINO)-1H-PYRAZOL-1-YL]ACETAMIDE AND N-(2,3-DIFLUOROPHENYL)-2-[4-({7-ETHOXY-5-[(2R)-PIPERIDIN.-2-YLMETHOXY]QUINAZOLIN-4-YL}AMINO)-1H-PYRAZOL-1-YL]ACETAMIDE FOR USE IN THE TREATMENT OF DISEASE | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007083096-A2 | N- (2, 3-DIFLUOROPHENYL) -2- [4- ( {7-METHOXY-5- [ (2R) -PIPERIDIN. -2-YLMETHOXY] QUINAZOLI N-4-YL}AMINO) -LH-PYRAZOL-1-YL] ACETAMIDE AND N- (2, 3 -D I FLUORO PHENYL) -2- [4- ( {7-ETHOXY-5- [ (2R) -PIPERIDIN. -2-YLMETHOXY] QUINAZOLIN | ASTRAZENECA AB (SE) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168143-A1 | QUINAZOLINE DERIVATIVES | CCNI, NQO2, MKI67 | EGFR 2065/4885DAGLB 4854/4885LTA4H 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.